The functional inactivation of the tumor susceptibility gene tsg101 in mouse NIH3T3 cells leads to cell transformation and the formation of metastatic tumors in nude mice. We cloned, mapped and sequenced the mouse tsg101 gene and further identi®ed a processed pseudogene that is 98% identical to the tsg101 cDNA. Based on Northern blot analysis, tsg101 is expressed ubiquitously in mouse tissues. A comparison of the coding region of the mouse tsg101 gene with the human TSG101 cDNA revealed that both the mouse and human gene encode ten additional highly conserved amino acids at the N-terminus. Based on the mouse tsg101 genomic structure, we predicted four additional introns within the human TSG101 gene. Their location was con®rmed using PCR and sequencing analysis. The presence of these so far unidenti®ed introns now explains published data on aberrantly spliced mRNA products that were frequently observed in primary breast tumors. We show that a majority of shorter TSG101 transcripts are not the result of aberrant splicing events, but represent a fraction of true alternative splice variants. Finally, we examined tsg101 expression patterns during dierent stages of mammary gland development and in dierent transgenic mouse models for breast tumorigenesis.
Introduction
The tumor susceptibility gene 101 (tsg101) was discovered in mouse NIH3T3 ®broblasts using a random homozygous knockout approach (Li and Cohen, 1996) . The functional inactivation of this gene leads to cell transformation in vitro and to metastasizing tumors in vivo when transformed mouse ®broblasts were transplanted into nude mice. Reversal of the neoplastic properties was obtained in vitro after deleting the gene that transactivated the antisense promoter using Cre-lox recombination. These results suggested that transformation and tumorigenesis were a direct consequence of TSG101 de®ciency (Li and Cohen, 1996) .
The tsg101 cDNAs in mouse and human are 86% identical on the nucleotide level . They both encode predicted proteins of about 43 kDa in size that show 94% similarity. On the subcellular level, the TSG101 protein is localized mainly in the cytoplasm (Zhong et al., 1997) but depending on the stage of the cell cycle it can be detected in the nucleus and it can co-localize with the mitotic spindle apparatus during cell division (Xie et al., 1998) . Another indication that TSG101 may have dierent functions at speci®c stages of the cell cycle is the presence of highly conserved motifs, such as a coiled-coil domain that is proposed to interact with stathmin (Maucuer et al., 1995) and a proline-rich region known to exist in activation domains of transcription factors . Furthermore, an N-terminal region is similar to the catalytic domain of ubiquitin-conjugating enzymes suggesting a potential role of TSG101 as a regulator in ubiquitin-mediated protein degradation (Koonin and Abagyan, 1997; Ponting et al., 1997) . The mechanism underlying cell transformation after inactivation of both tsg101 alleles is not known. Potentially as a regulator of protein degradation, TSG101 could in¯uence the half-life of other important tumor suppressors and regulatory factors of the cell cycle. Since inactivation of TSG101 was observed to be associated with abnormal microtubule organizing centers and nuclear anomalies, it is suggested that the absence of the TSG101 protein or the lack of individual TSG101 domains may lead to chromosomal instability and, thereby to a progression of tumorigenesis (Xie et al., 1998) .
The human TSG101 gene has been mapped to a speci®c chromosomal region on chromosome 11, p15.1-p15.2 , that is associated with a loss of heterozygosity in dierent types of tumors such as breast cancer (Ali et al., 1987) and Wilms' tumor (Reeve et al., 1989) . However, rearrangements and somatic mutations within the TSG101 gene are rare events in human breast cancers (Steiner et al., 1997; Gayther et al., 1997; Lee and Feinberg, 1997; Wang et al., 1998) . Instead of gene alterations, aberrant TSG101 splice forms have been correlated to cell transformation (Gayther et al., 1997; Sun et al., 1997; Lee and Feinberg, 1997) . In order to identify the structural basis of the aberrant transcripts, the intron-exon architecture of the TSG101 gene needs to be determined. This information and the identi®cation of regulatory elements within the promoter will provide new insights into TSG101 transcriptional regulation, alternative and aberrant mRNA splicing events, resulting protein variants, and gene function in normal and transformed tissue.
Results

Genomic organization of the mouse tsg101 gene
The mouse tsg101 gene was cloned as multiple overlapping restriction fragments from two individual BAC genomic clones. Brie¯y, a cDNA that was generated by RT ± PCR from mammary tissue of a lactating dam was used to probe a 129/SvJ genomic BAC library (see Material and methods). Six positive BAC clones were analysed and ®ve contained a novel processed tsg101 pseudogene but not the actual tsg101 gene. In order to distinguish the true gene from the pseudogene, we designed a PCR assay that ampli®ed intron sequences (see Materials and methods). The sixth BAC clone contained the genuine tsg101 gene. Since this BAC clone lacked the 5' part of the tsg101 gene a second overlapping BAC clone was isolated. Overlapping subclones were sequenced and the size of the mouse tsg101 gene was determined to be 33.6 kb (GenBank AF060868). Furthermore, we identi®ed additional introns, which had not been predicted from mapping studies . In addition, we determined dierences in the coding region of the mouse tsg101 gene to the previously published mouse cDNA sequence (Li and Cohen, 1996) . These dierences lead to an expansion of the tsg101 reading frame that encodes ten additional amino acids at the N-terminus, which are highly similar to the predicted human TSG101 protein.
The murine tsg101 gene contains ten exons (Figure 1 ). Sequences of intron-exon junctions are summarized in Table 1 . Evidently, the larger number of exons and introns of the murine tsg101 gene compared to the human homologue is the result of four additional introns within a region considered to be the ®rst exon of the human gene . The ®rst exon includes the 5' untranslated sequence and the translation initiation codon. With 329 bp, exon 10 is the largest exon, but it contains almost 75% of its nucleotides (240 bp) as 3' untranslated sequence. A comparison of the coding region to the previously published mouse cDNA sequence (Li and Cohen, 1996) revealed several dierences. An insertion of two G residues between position 37 and 38 of the published mouse cDNA shifts the ®rst ATG codon in position 33 in frame with the tsg101 coding region. This results in the expansion of the tsg101 open reading frame of exactly 30 nucleotides encoding ten additional amino acids at the N-terminus (Met-Ala-Val-Ser-Glu-Ser-Gln-Leu-Lys-Lys). The hypothesis that the ATG at position 33 is the preferred translational start site is supported by the fact that this ATG codon is¯anked by a C-rich sequence motif in position 76 to 71 and a highly conserved G in positon +4 (Kozak, 1997) . A mismatch at position 81 (T to C) is similar to the human sequence and did not result in any amino acid substitution. Some additional changes of single nucleotides were observed in the 3' untranslated region immediately following the translational stop codon.
A prominent part of the TSG101 protein, an a-helix domain that forms a coiled-coil structure, was reported to be identical to CC2 and has been proposed to interact with stathmin (Maucuer et al., Figure 1 Genomic structure of the mouse tsg101 gene. The numbered boxes illustrating exons 1 ± 10 are not in scale. Solid bars represent known encoded protein domains 1995). This particular domain is encoded by two of the largest coding exons of tsg101, exon 8 and 9 (Figure 1 ). The proline rich region, which is known to be characteristic for transcription factors, is entirely encoded by exons 5 ± 7. Both groups of exons encoding the a-helix domain and proline rich region are separated by the largest intron of more than 8 kb. Recently, it was reported that the N-terminal region of TSG101 has a sequence similarity to the catalytic domain (UBC) of ubiquitin-conjungating enzymes E2 and UBC-related DNA-binding proteins (Koonin and Abagyan, 1997; Ponting et al., 1997) . Nucleotide sequences encoding conserved amino acid residues of TSG101 and other E2 derivatives are scattered within the ®rst ®ve exons.
A 2.9-kb fragment spanning the promoter/upstream was sequenced. Sequences surrounding the putative transcriptional start site (Li and Cohen, 1996) have features characteristic of a house-keeping gene promoter. It lacks both TATA and CAAT boxes, has a high GC content, and contains several potential Sp1 and AP2 consensus sites (Figure 2 ). The tsg101 5' region also contains putative sites for nuclear factor GAPBF2 known to exist in promoters of other ubiquitously expressed genes (Aki et al., 1997) .
The mouse genome carries a tsg101 pseudogene Initially, we probed a lambda phage library containing 129SVJ mouse genomic DNA with a cDNA probe (see Materials and methods) and isolated ten phage clones. The presence of the tsg101 gene within the recombinant phage DNA was tested by PCR using primers from the 3'-untranslated region as described by Li et al. (1997) . Inserts of two PCR positive lambda clones were sequenced. The resulting sequence (GenBank AF060867) was 98% identical to the mouse tsg101 cDNA and did not contain any introns suggesting the presence of a pseudogene. The processed pseudogene diers in a few signi®cant mutations from the murine cDNA. The AT-deletion at position 153 results in a frame shift and a precocious termination of the open reading frame. The presence of the pseudogene in other lambda phages could be easily detected by PCR and subsequent NdeI restriction digest. The AT-deletion in the pseudogene eliminates the NdeI recognition site Figure 2 Nucleotide sequence of the mouse tsg101 5'-¯anking region. The transcriptional start site (Li and Cohen, 1996) and exon 1 is indicated in bold and upper case; the following intron sequence is shown in normal lower case. The newly suggested translation start codon (ATG) is double underlined. Nucleotides numbering on the right refers to the distance in bp to the translation start codon. Locations of putative responses elements in the 5'-¯anking region are boxed (GAPBF2) and underlined (SP1 solid line; AP2 dashed line) present in the mouse tsg101 cDNA. Interestingly, a downstream ACCC-deletion at position 269 shifts an ATG codon at position 246 into frame with the rest of the original tsg101 reading frame. Since the 5'-¯anking region of the pseudogene shows no similarity to the promoter region of the tsg101 gene and secondly, the ATG does not contain any consensus sequence for initiation of translation (Kozak, 1997) , it is very unlikely that the pseudogene is expressed. To identify potential tsg101 pseudogene transcripts, we screened 222 mouse tsg101 ESTs using BLAST 2.0. None of the ESTs carried any characteristic mutations for the pseudogene. Moreover, we performed a RT ± PCR ampli®cation of a 300 bp region¯anking the NdeI recognition site that is speci®c for the actual tsg101 gene. The RT ± PCR product was completely digested with NdeI restriction enzyme into expected smaller fragments (data not shown). Taken together, there is no experimental evidence that the pseudogene is expressed.
Determination of the structure of the human TSG101 gene
We have cloned and sequenced the entire mouse tsg101 gene. The mouse tsg101 gene diers not only in size, but also in the number of exons and introns, and intron sizes from the architecture of the human gene, which had been mapped by restriction analysis . To compare the location of intron sites between the mouse and human TSG101 gene, we aligned the coding sequence of the mouse gene to the human TSG101 cDNA . Sequences anking the exon junctions of the mouse tsg101 gene and the corresponding nucleotides of human cDNA are illustrated in Table 2 . The results show a very high similarity on the nucleotide level in this particular region and the ®rst nucleotide of subsequent exons is entirely conserved. Based on these data we could predict the location of introns within the human TSG101 gene at a level of a single nucleotide in areas that were predicted earlier to contain intron sequences . In addition, we determined four additional introns in the sequence considered being the ®rst exon. We experimentally tested the presence of those four additional introns by PCR ampli®cation of human genomic DNA using primers corresponding to the human coding sequence, which¯ank the anticipated intron sites. The PCR ampli®cation products are shown in Figure 3 . As predicted, the human gene also contains four additional introns. We also ampli®ed previously predicted intron sequences to accurately determine their location. The PCR fragments were gel puri®ed and sequenced, and the sequences of all intron-exon junctions within the human TSG101 gene are summarized in Table 3 . As predicted from the alignment of the mouse and human cDNAs, the intron-exon boundaries are conserved between both species on the level of a single nucleotide (compare Tables 2 and 3) . We were not able to amplify intron 7 from human genomic DNA probably because of its larger size similar to the mouse counterpart (Figure 1 ). Taken together, not only the mRNA and amino acid sequences of the mouse and human TSG101 protein are highly conserved, but also the entire structure of the TSG101 gene is similar between both species. This supports earlier suggestions that the mouse and human TSG101 gene are true gene homologues and that they must have fundamental biological functions in common.
Expression of the mouse tsg101 gene in various organs and the developing mammary gland Sequencing data of the 5'¯anking region of the mouse tsg101 gene exhibited several features that indicate that this gene might be constitutively expressed in many tissues. To test this hypothesis we analysed the expression of tsg101 in several organs of adult mice (Figure 4a ). Total RNA was analysed using a 32 Plabeled cDNA. Tsg101 was highly expressed in all organs examined. The highest expression was observed in brain and mammary tissue and the lowest expression was detected in liver. These Northern blot data support our hypothesis that tsg101 might be ubiquitously expressed in all mouse organs and con®rm earlier studies in various human tissues .
It was suggested that the tsg101 gene is involved in cell growth, dierentiation and mammary neoplasia Xie et al., 1998) . To explore the role of tsg101 in normal breast development, we established its expression pro®le at dierent stages of mammogenesis (Figure 4b ). Tsg101 was expressed highly at all stages of mammary gland development. A slight downregulation at the transcriptional level was detected at early and mid pregnancy. This phase of mammary gland development is characterized by massive epithelial cell proliferation.
Tsg101 transcription in primary breast tumors of transgenic mouse models A reduced amount of full-length TSG101 transcripts and the presence of truncated mRNA forms have been correlated to various stages of tumorigenesis in human mammary tissue (Gayther et al., 1997; Lee and Feinberg, 1997; Li et al., 1997) and other malignancies (Sun et al., 1997) . We have now analysed tsg101 transcription in established transgenic mouse models for breast cancer to address the question, whether tsg101 expression is altered in primary tumors. Biopsies of mammary tumors were taken from transgenic mice expressing dierent oncogenes under the control of mammary speci®c regulatory elements of the whey acidic protein (WAP) gene. Speci®cally, tissue was harvested from mice expressing transgenic Int3, SV40-TAg and TGFa. Total RNA was isolated and analysed on Northern blots ( Figure 5 ). Full-length tsg101 trancripts were found in all tumor samples. The level of tsg101 transcription was not altered in tumors from WAP-TAg and WAP-TGFa transgenic mice. In contrast, a sharp reduction of tsg101 expression was observed in WAP-int3 mammary tumors. A comparison of tsg101 expression in solid tumors and adjacent mammary tissue of the same animal ( Figure 5 , lanes 2 ± 5) demonstrated reduced levels of tsg101 mRNA in Int3 tumors (64 and 36%, respectively). We were not able to detect smaller truncated tsg101 transcripts (data not shown), which suggests that the decreased amount of full length mRNA is not the result of aberrant or alternative splicing.
Discussion
The human TSG101 gene has been mapped on chromosome 11 band p15 , a region that is known to be associated with a loss of heterozygosity (LOH) in human breast cancers (Ali et al., 1987) and Wilms' tumors (Reeve et al., 1989) . Aberrant TSG101 transcripts have been detected in a number of primary human breast cancers and other tumors Gayther et al., 1997; Lee and Feinberg, 1997; Sun et al., 1997) , but intragenic deletions of the TSG101 gene are rare events in human malignancies (Steiner et al., 1997 Feinberg, 1997; Wang et al., 1998) . It was proposed that shorter transcripts are caused by abnormal splicing events recognizing cryptic splicing donor and acceptor sites within exons (Gayther et al., 1997; Lee and Feinberg, 1997) . Based on our analysis of the mouse and the human TSG101 genes we suggest that many of the reported aberrant transcripts are in fact alternative splice forms. We show that part of the TSG101 coding sequences, which had been described as the ®rst exon, actually spans four exons, and that exon skipping results in dierent RNA forms, which had been described in tumors and normal tissues of dierent origin.
How similar are the human and mouse TSG101 genes?
We have cloned and sequenced the entire murine tsg101 gene. A comparison of the mouse genomic sequence with the map of the human counterpart revealed dierences in size and in the number of exons. The mouse gene consists of ten exons and spans about 33.6 kb. In contrast, the human gene cloned from a PAC library was estimated to be much smaller in size and to contain six exons . The ®rst exon of the human TSG101 gene was represented by ®ve exons in the mouse. A comparison of the mouse tsg101 coding region with the corresponding human cDNA illustrated that the junctions of all exons in the mouse gene were preserved in the human cDNA, suggesting that the human gene may also contain additional exons. Indeed, we cloned and veri®ed the existence of four additional introns in the human gene. In addition to those four introns, we ampli®ed earlier predicted introns , determined their sizes and demonstrated their accurate location. A reexamination of the human TSG101 cDNA with the revised mouse sequence revealed an ATG start codon 30 nucleotides 5' of the previously published translational initiation site. Our data suggest that the human TSG101 protein contains the same ten additional N-terminal amino acids. The expansion of the open reading frame of the mouse and human TSG101 gene was found independently by Li and coworkers and the database entries in GenBank were updated (U52945 and U82130) and match with our genomic sequence.
Taken together, not only the mRNA and amino acid sequences of the mouse and human TSG101 protein are highly conserved but also the entire structure of the TSG101 gene is identical in both species.
Aberrant vs alternative splicing
Several reports demonstrated the presence of aberrantly spliced TSG101 transcripts in tumor specimen (Gayther et al., 1997; Lee and Feinberg, 1997) . Based on our ®ndings that the human TSG101 gene contains additional introns, we re-analysed published data about aberrant splice products. We suggest that many truncated transcripts frequently observed in tumors and nonmalignant tissues are true alternative splice products, rather than aberrant transcripts. For instance, type B (133 ± 731), C (133 ± 639) and D (133 ± 448) deletions observed in primary breast tumors (Lee and Feinberg, 1997) are true alternative splice products ( Figure 6 ). All three alternative splice variants were also reported as aberrant transcripts to occur in human malignancies other than primary breast tumors (Gayther et al., 1997) and normal tissues of dierent origin (Gayther et al., 1997; Lee and Feinberg, 1997) . The most frequently observed alternative splice variant in normal human tissues (about 50% of all abnormal variants) is the 133 ± 448 deletion (Gayther et al., 1997; Lee and Feinberg, 1997) . Interestingly, this is the only type of alternative splice product that would result in an in-frame deletion. If translated, this particular mRNA would create a short TSG101 protein lacking domains encoded by exons 2, 3 and 4, which represent a considerable portion of conserved amino acid residues to the catalytic domain (UBC) of ubiquitin-conjungating enzymes E2 and UBC-related DNA-binding proteins. It needs to be determined whether such a smaller TSG101 protein variant can interfere with the potential role of TSG101 as a regulator in ubiquitin-mediated protein degradation or other speci®c functions.
Despite the presence of alternative splice variants of TSG101 transcripts, some reported shorter transcripts are probably real aberrant splice forms. For instance, a frequently observed aberrant TSG101 mRNA contains a 153 ± 1053 deletion (Gayther et al., 1997; Lee and Feinberg, 1997; Sun et al., 1997) . We con®rmed by sequencing and by PCR using primers¯anking both cryptic splicing donor and acceptor sites within exons that no extra introns are located at those positons in exon 2 and exon 9 of the human TSG101 gene (data not shown). Therefore, the 153 ± 1053 deletion in the human TSG101 mRNA appears to be a real aberrant splice product. It does not encode any known functional domain of the TSG101 protein and, therefore, its biological role during tumorigenesis is not clear. Moreover, this particular mutation is not restricted to neoplastic tissues since it is also found in normal breast tissue and various other organs (Lee and Feinberg, 1997; Gayther et al., 1997) .
Taken together, our ®ndings suggest that shorter transcripts are caused by splicing events at either existing intron ± exon junctions (alternative splicing) or cryptic splice donor and acceptor sites within exons (aberrant splicing). Therefore, our data invalidate the 7) and WAP-SV40Tag (lanes 8 and 9) were analysed. Twenty mg of total RNA was separated in 1.5% agarose gels containing 18% formaldehyde, transferred to a membrane and hybridized with a 32 P-labeled tsg101 cDNA probe hypothesis that anomalous transcripts are pure PCR artifacts as proposed by Hampl et al. (1998) . It remains to be established if alternative splice variants of TSG101 encode functional proteins, and if such shorter proteins can interfere with the function of the wildtype TSG101 protein.
Does the human genome possess TSG101 pseudogenes?
We have cloned and sequenced a processed tsg101 pseudogene from a mouse genomic library that is 98% identical to the murine tsg101 cDNA. A Southern blot examination of human genome DNA with various short cDNA probes revealed an unusual fragment pattern (Steiner et al., 1997) that was dierent from the map provided earlier . These results do not only indicate that the genomic map is incomplete because of missing introns, but it could also suggest that there are pseudogenes in the human genome. However, based on a PCR assay multiple exon-speci®c primers to amplify intron sequences (Figure 3) we did not identify a human TSG101-derived processed pseudogene, which would result in very short PCR fragments. Whereas pseudogenes do not interfere with the analysis of genomic sequences in human samples, the existence of pseudogenes in the mouse genome has profound implications on the design of assays to detect tsg101 gene deletions and gene expression patterns by PCR, the cloning of new genes with sequence similarities to tsg101, and mutational analyses of the tsg101 locus to study the gene function in vivo.
Transcriptional activation of the tsg101 gene in various tissues and the developing mammary gland
The 5'¯anking region of the tsg101 gene exhibited features of housekeeping gene promoters, such as a high GC content and potential Sp1, AP2 and GAPBF2 consensus sites. Initial expression studies on mRNA from human tissues revealed that TSG101 is expressed in a variety of organs . All mouse tissues we examined contained a tsg101 transcript of about 1.2 kb in size, which support the hypothesis that tsg101 is expressed ubiquitously. While brain and mammary gland show the highest expression levels, less tsg101 mRNA was detected in liver. Interestingly, the high amount of tsg101 transcripts in brain correlates with the expression pro®le of stathmin mRNA. Stathmin, which is suggested to interact with the a-helical (cc2) domain of the TSG101 protein, is most abundant in brain and neurons (Ozon et al., 1997) . The hypothesis that tsg101 might be essential for common functions in a living cell is supported by the fact that this gene is expressed throughout development. A search for sequence similarities of the full length mouse tsg101 cDNA in the mouse ESTs database (BLAST 2.0) indicate that tsg101 transcripts are already present in 1-cell and 2-cell stage embryos.
From in vitro data it has been suggested that tsg101 is involved in cell growth and dierentiation (Xie et al., 1998) . Tsg101 is expressed at all stages of mammogenesis regardless of their proliferative and dierentiation status. A slightly reduced transcriptional level was detected at early to mid-pregnancy, a time of massive cell proliferation. A downregulation of tsg101 at the peak of alveolar proliferation would support the hypothesis that the TSG101 protein might be a negative growth regulator (Watanabe et al., 1998) . Indeed, a strong overexpression of this molecule in vitro leads to the inhibition of cell division and, eventually, cell death (Xie et al., 1998; Wagner, unpublished) . Nevertheless, the reduction of tsg101 transcripts in vivo in the developing mammary gland is moderate. Our observations support earlier ®ndings in vitro (Xie et al., 1998) that the level of tsg101 expression is independent from the stage of the cell cycle. Therefore, it can be assumed that dierences in the activity of TSG101 are regulated primarily at the point of protein synthesis and modi®cation such as phosphorylation, and/or heterodimerization with other binding partners, such as stathmin.
Regulation of tsg101 expression in primary tumors from transgenic models for breast cancer
The overexpression of oncogenes and growth regulators in mammary epithelial cells can lead to cellular transformation and tumor progression. Transgenic mouse models have been generated to decipher the molecular pathways leading to tumorigenesis. We investigated the transcriptional activation of the tsg101 gene by Northern blot analysis in three wellestablished models that develop breast cancer through distinct signaling cascades. First, pathways eecting involution, programmed cell death and remodeling are impaired in transgenic mice expressing TGFa (Sandgren et al., 1995) . Secondly, we investigated tsg101 expression in WAP-SV40 large T antigen (SV40-Tag) transgenic mice (Tzeng et al., 1993) . SV40-Tag is known to bind and inactivate molecules that are linked to the cell cycle such as Rb and p53, but p53-independent pathways of programmed cell death are not aected . Thirdly, we studied a mouse model expressing a tumor speci®c truncated form of the murine int3 gene, a Drosophila Notch4-related cell fate protein. Int3 inhibits the growth and dierentiation of the mammary lobulo-alveolar compartment and leads to mammary dysplasia, tumorigenesis, and lung metastases.
Transgenic mice expressing TGFa and SV40-Tag did not show any reduction in tsg101 expression. These data suggest that tsg101 expression is not altered when apoptosis is inhibited (WAP-TGFa) or induced (WAP-SV40-Tag). Moreover, these data support the hypothesis that tsg101 trancription is not linked to the cell cycle since the functional inactivation of Rb and p53 has no in¯uence on the mRNA level of tsg101. Therefore, WAP-TGFa and WAP-SV40-Tag transgenic mice do not serve as an appropriate model to study the transcriptional inactivation of tsg101 during the progression of tumor formation. A reduction of tsg101 mRNA was, however, observed in mice expressing int3 under the control of WAP regulatory elements. Total RNA from tumors was compared to adjacent mammary tissues of the same transgenic animals to determine whether the downregulation of tsg101 is a direct eect of the transgene expression or a secondary event in the progression towards cancer. Full length tsg101 transcripts were present in both fractions, however, the tumors contained less tsg101 mRNA. The reduction was not the result of aberrant or alternative splice forms. The mechanisms of Notch4/ Int3 signaling in the mammary gland is still unresolved. The only int3 mutation that leads to the formation of tumors is caused by MMTV proviral integration and the subsequent expression of a truncated protein, which consists of the intracellular domain of int3 (Gallahan and Callahan, 1997) . From studies in Drosophila and C. elegans it is suggested that the intracellular domain of Notch4 localizes to the nucleus and that it interacts with proteins that regulate gene transcription (for references see Greenwald, 1998) . It needs further investigation if tsg101 expression is directly regulated by mechanisms downstream of the Notch4/int3 cascade, or if the downregulation of tsg101 is a secondary event during tumorprogression.
The functional role of TSG101 during cell proliferation, dierentiation and tumor formation remains to be determined. It has been suggested that TSG101 acts primarily as a`care taker' rather than a`gate keeper' (Xie et al., 1998) . This includes the regulation of ubiquitin-mediated protein degradation of other important tumor suppressors, or TSG101 could act as a`care taker' for chromosomal stability during cell division. In future studies it will be important to investigate the loss of TSG101 function in vivo in conjunction with tumor progression. Since a functional knockout using an antisense strategy could lead simultaneously to an inactivation of other genes with partial sequence similarities to tsg101, it remains to be determined if a tsg101 gene deletion approach could also result in a neoplastic transformation and tumor progression. However, a conventional gene targeting and knockout approach could lead to an early embryonic lethality since tsg101 is ubiquitously expressed at all stages of development. A more defined tissue-speci®c deletion of the tsg101 gene in the mammary gland using the Cre-lox recombination system (Wagner et al., 1997) could be a practicable solution to study the loss-of-function during proliferation and dierentiation in vivo.
Materials and methods
Cloning of a mouse tsg101 cDNA probe A cDNA corresponding to the mouse tsg101 mRNA was cloned by RT ± PCR. Total RNA was isolated from mouse mammary tissue 24 h post-partum according to Chomczynski and Sacchi (1987) . One microgram of RNA was reverse transcribed at 378C for 1 h in a total volume of 20 ml using MLV reverse transcriptase (Gibco ± BRL) and a gene-speci®c primer (5'-TTC GTT TCA AGG CAT TAA GCT C-3'). Subsequently, the RT reaction mix was heated at 958C for 10 min and an aliquot of 10 ml was used for ampli®cation in a 100 ml PCR reaction using tsg101-speci®c forward and reverse primers (5'-CAT GGC TGT CCG AGA GTC AGC-3' and 5'-CTG TGA GCT TGT TTG GGC AGG G-3'). The PCR conditions were 3 min 948C, 35 cycles (45 s 948C, 45 s 658C, 60 s 728C), 5 min 728C, 48C. The ampli®cation products were separated on a 2% agarose gel and the expected band of about 600 bp was puri®ed using the QIAquick gel extraction kit (Qiagen). The tsg101 cDNA probe, after sequencing analysis, was subcloned into the pZERO-1 vector (Invitrogen) and used for hybridization and cloning of tsg101 genomic DNA and Northern blot analysis.
Cloning of the mouse tsg101 gene and a processed pseudogene Initially, we screened a lambda phage mouse genomic library (129/SVJ Lambda FIX II, Stratagene) following the manufacture's protocol with 32 P-labeled tsg101 cDNA (Random Priming Kit, Stratagene). The plaques were further screened with PCR using mouse-speci®c primers for tsg101 . After sequencing of subcloned fragments we con®rmed that the PCR positive plaques contained a processed pseudogene but not the tsg101 gene. Since pseudogenes show a much stronger signal of several magnitudes during the plaque-screening assay that makes it more dicult to ®nd the actual gene, we switched from a lambda phage to a BAC library (FBAC-4431, Genome Systems, Inc). Filters containing arrayed BAC clones were hybridized again with tsg101 cDNA according to the manufacture's protocol. Six positive BAC clones were evaluated further by PCR to con®rm the presence of the tsg101 gene and to eliminate clones that contained pseudogenes. Therefore, we had to set up a PCR assay to detect speci®cally the actual tsg101 gene. We assumed that mouse tsg101 gene would have the same overall structure as the human gene that was published previously . We designed various primers within exons to amplify intron sequences. Initially, we tested those primers with genomic DNA derived from murine embryonic stem cells. Only one set of primers (5'-CCT TGG AGA AGC TTT GCG GCG-3' and 5'-TAG CCC AGT CAG TCC CAG CAC AGC ACA G-3') that ampli®ed the last intron showed expected PCR fragments of about 1.6 kb for the TSG101 gene and 350 bp for the tsg101 pseudogene. The 1.6 kb PCR fragment was subcloned and the presence of both intron-exon junctions were con®rmed by sequencing. We used the same primer set to screen individual BAC clones that hybridized the tsg101 cDNA probe. Five out of six BAC clones contained the pseudogene and only one contained the actual gene for tsg101. None of the clones had both sequences. The BAC clone containing the tsg101 gene was mapped using Southern hybridization. Multiple fragments were subcloned into pZERO-1 vector (Invitrogen) and sequenced using a standard protocol for cycle sequencing (Perking Elmer). The Sequencher software (Gene Codes, Corp.) was used to align and assemble individual sequences. Since the BAC clone did not contain the ®rst exon and the 5' anking region, we isolated a 500 bp fragment of the most ®ve prime part of the tsg101 clone and used this fragment as a probe to rehybridize the BAC library. We isolated a second BAC clone containing the missing ®rst exon and more than 100 kb of 5'¯anking region of tsg101. This clone had only 5 kb overlapping sequence in common with the ®rst clone.
Isolation of total RNA and Northern blot hybridization RNA of normal mammary gland tissues and tumors was isolated following a procedure by Chomczynski and Sacchi (1987) . The total RNA (20 mg per lane) was separated in 1.5% agarose gels containing 18% (v/v) formaldehyde, transferred to a GeneScreen Plus membrane (Dupont) and hybridized with tsg101 cDNA as described above.
Transgenic mice
Transgenic mice expressing int3 (Gallahan et al., 1996) , SV40-TAg (Tzeng et al., 1993) , and TGFa (Sandgren et al., 1995) cDNAs under regulatory elements of the WAP gene have been characterized previously. All mouse models developed mammary tumors after several pregnancies. The tumor samples were taken post mortem. RNA was isolated and Northern blot hybridization was performed as described above. Radioactive signals were measured using a phosphorimager (Fuji) and the quantity of tsg101 transcripts was corrected by the amount of total RNA present in each lane (18S rRNA).
PCR ampli®cation of intron sequences within the human TSG101 gene
